Alcestobart is named as an intervention in 3 current clinical trials in our China, USA, Australia, Mexico, France, Spain, Italy, Canada, Brazil, South Korea and Singapore registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is BeiGene (2). The most-studied condition is Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430 · ClinicalTrials.gov ↗ · Advanced Melanoma
|
Phase 1/2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | China |
|
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708 · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
|
Phase 2 | Active, closed | BeiGene | USA, China, France, Spain, Italy, Canada, Brazil, South Korea, Singapore, Australia |
|
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
|
Phase 1/2 | Active, closed | BeiGene | USA, China, Mexico, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| BeiGene | 2 |
| Nanjing Leads Biolabs Co.,Ltd | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, USA, Australia, Mexico, France, Spain, Italy, Canada, Brazil, South Korea and Singapore registers name Alcestobart (also registered as LBL-007) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
BeiGene (2) and Nanjing Leads Biolabs Co.,Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Alcestobart works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Alcestobart works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Alcestobart (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.